Evaluation of Immunostimulatory Activities of Synthetic Mannose-Containing Structures Mimicking the β-(1→2)-Linked Cell Wall Mannans of Candida albicans

Kaarina Ranta, Kaisa Nieminen, Filip S. Ekholm, Moniká Poláková, Mattias U. Roslund, Tiina Saloranta, Reko Leino, and Johannes Savolainen

Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland; Laboratory of Organic Chemistry, Åbo Akademi University, Åbo, Finland; and Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia

Immunostimulatory properties of synthetic structures mimicking the β-(1→2)-linked mannans of Candida albicans were evaluated in vitro. Contrary to earlier observations, tumor necrosis factor (TNF) production was not detected after stimulation with mannobetaes in mouse macrophages. Divalent saccharide 1,4-bis(α-D-mannopyranosyloxy)butane induced TNF and some molecules induced low levels of gamma interferon (IFN-γ) in human peripheral blood mononuclear cells (PBMC).

Immunostimulatory molecules intensify and modify the lymphocyte-mediated immune response and its duration. Such molecules can, therefore, be potentially applied as adjuvants in vaccines and allergy preparations. Generally, allergen vaccines function by balancing the T helper 2 (Th2)-type responses by inducing Th1- and T regulatory-type responses (2, 3, 20, 21, 30, 31, 33).

β-(1→2)-Oligomannoside constituents of the Candida albicans cell wall have been shown to possess immunostimulatory properties, as evidenced by induction of cytokine production, including tumor necrosis factor (TNF) production, in humans and mice (6, 14, 16, 18, 19, 29, 34, 35, 36, 37). In particular, the oligosaccharide fractions consisting of four or more mannose units, isolated and fractionated from the C. albicans cell wall, have been shown to induce TNF production in mouse macrophages (19). However, being isolated from cell walls, such fractions may, at least in part, be contaminated with other biomolecules, including mannoproteins consisting of both oligosaccharides and proteins, which all may contribute to the biological activities observed. Therefore, biological studies employing well-defined synthetic β-(1→2)-linked oligomannoside compounds are of interest for verifying and studying in detail the proposed immunostimulatory properties of such constructs.

For the present biological study, 15 mannose-containing structures, a majority of these with β-(1→2)-linkages (Fig. 1A, 2A, 3A, and 4A), were prepared by applying and further modifying the recently developed methodologies for construction of β-(1→2)-mannosidic linkages by Crich and others (7). The synthesis procedures have been published previously by us (9, 10, 28). The compounds prepared were designed as simple mimics and analogues of the hydrolyzed oligosaccharide fractions from the C. albicans cell wall, with the β-(1→2) linkage serving as a basis for all structural modifications. Mild-acid-hydrolyzed C. albicans mannan was used as a positive control in all cell culture experiments. Initially, C. albicans mannan was prepared with the Cetavlon method as previously described (27); thereafter, it was hydrolyzed in mild acidic conditions with 0.1 N HCl for up to 60 min at 100°C. Neutralization of hydrolysis products was performed by adding NaOH. The outcome of the hydrolysis was analyzed by thin-layer chromatography (TLC) using silica gel-coated aluminum sheets (Merck, Darmstadt, Germany) and n-butanol-acetic acid-water (2:1:1 vol./vol./vol.) as an eluent. C. albicans mannan and all synthetic compounds were screened for endotoxin contamination with the E-Toxate kit (Sigma-Aldrich, St. Louis, MO) by spot-checking during preparation and by double-checking all compounds showing any immunostimulatory activity (compounds 1, 2, and 10). Endotoxin levels in all tested samples (highest used stimulation concentration) were below 0.015 endotoxin units (EU)/ml.

Different concentrations of the synthetic β-(1→2)-linked mannobetaes (compound 3) were cultured for 24 h with cells from the mouse macrophage cell line J774.2 (lot 06/C/015; Sigma-Aldrich, Germany). TNF production was measured with the high-sensitivity mouse TNF cytokine Lincoplex kit (Linco Research, St. Charles, MO).

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples donated by voluntary laboratory personnel after informed consent by Ficoll-Paque density gradient centrifugation (Ficoll-Paque PLUS; GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Cells were resuspended in RPMI-based culture medium and stimulated on 48-well flat-bottomed cell culture plates at a density of 10^6/ml as previously described (31). The cells were stimulated with the compounds (1 to 15) (0.2 to 100 μg/ml), and medium alone served as an unstimulated control. After 72 h, the cells were collected and centrifuged. DNA was extracted from the pellets, cDNA synthesis was performed, and relative quantitation of cytokine mRNA expression in the PBMC was performed by TaqMan PCR using the ABI Prism 7700 sequence detection system as described previously (26). The data analysis was performed according to the manufacturer’s instructions (User Bulletin number 2, P/N 4303849; Applied Biosystems) using a comparative threshold cycle (C_T) (2^(-ΔΔC_T}) method, in
which β-actin served as an endogenous reference gene and unstimulated cell culture served as a calibrator. The resulting $2^{-\Delta\Delta CT}$ value was used to indicate the fold change in cytokine expression relative to that of unstimulated cultures.

The cytokines in supernatants (gamma interferon [IFN-γ], interleukin-4 [IL-4], IL-10, and TNF) were measured with high-sensitivity human cytokine Lincoplex kits (Linco Research, St. Charles, MO, USA). The Lincoplex assays were performed in accordance with the manufacturer’s protocol by employing Luminex technology. The study was approved by the local ethics committee.

In the present study, the synthetic β-(1→2)-linked mannotetraose (compound 3) did not induce any detectable TNF production in a mouse macrophage cell line. Under the same experimental conditions, the mild-acid-hydrolyzed C. albicans mannan induced TNF production (Fig. 1B). In an earlier work by Poulain and coworkers, similar mannotetraose-containing fractions prepared by acidic hydrolysis and subsequent fractionation of the C. albicans cell wall oligosaccharides induced TNF production in peritoneal mouse macrophages (19). In addition, native fractions containing β-(1→2)-linked oligomannosides with a degree of polymerization (DP) of eight or more appeared to improve the induction of TNF secretion (19). It should be noted that in that study, the macrophages were purified from peritoneal exudate cells of 20- to 24-week-old BALB/c mice, whereas the present work was performed with immortalized macrophages from a mouse cell lineage, a difference which may partially explain the contradictory results obtained.

It is known that J774 mouse macrophage cells are heterogeneous and dependent on several factors in their expression of the macrophage mannose receptor (MR) (11,32). It is thus possible that the expression of the functional mannose receptor was low or absent in our experiments. MR and dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) are well documented for their capacity of recognizing N-linked mannans (1, 5). However, macrophage activation by β-(1→2)-linked mannoside structures is not dependent solely on MR because the recognition of the different components of the C. albicans cell wall by immune cells is mediated by a diverse range of pattern recognition receptors (29). In addition, responses by β-(1→2)-linked oligomannoside stimulation are mediated through galectin 3, a 30-kDa receptor expressed on macrophages,
dendritic cells, and epithelial cells (13, 17, 23). The contact between galectin 3 and the \( 9252 -(1\rightarrow2) \)-oligomannosides of the \( 9251 \) cell wall is essential in \( 9252 \) colonization and invasion (8) as well as recognition of \( 9252 \) by murine macrophages (12). Since acid-hydrolyzed mannan, containing \( 9252 -(1\rightarrow2) \)-oligo-
mannosides, induced TNF production by the J774 cells, the neg-
ative results with the synthetic mannotetraose cannot be ex-
plained solely by a lack of macrophage mannose receptor
expression alone. A possible explanation for our results is that, in
the earlier studies, the oligomannoside fractions evaluated may
have been cell wall glycoproteins comprising both carbohydrate
and protein. In the present study, well-defined, chemically synthe-
sized mannosides without a protein component were used, and
accordingly, the responses detected can only be due to interactions
between the pure small carbohydrate residues and the macro-
phages. As such, these interactions appear inadequate to induce
TNF production.

Structural details concerning the possible interactions between
oligomannosides and human lymphoid cells have remained
largely unknown. It is, nevertheless, reasonable to assume that the
interactions between the sugar moiety and the cell depend on both
the valency and the three-dimensional structure of the carbohy-
drate (26). These, in turn, are influenced by chain length, stereo-
chemistry, and the nature of the glycosidic linkages and the indi-
vidual sugar units. In the present work, variations of these
parameters were aimed at when selecting and constructing the
compounds for the biological screening. As an indicator of Th1
immunostimulation, the main Th1-type cytokine, IFN-

FIG 3 (A) Glucose-containing structures of methyl 2-acetamido-2-deoxy-\( 9252 \)-
glucopyranosyl-(1\rightarrow2)-\( 9251 \)-mannopyranoside (7), methyl \( 9252 \)-glucopyranosyl-
(1\rightarrow2)-\( 9251 \)-mannopyranoside (8), and methyl \( 9252 \)-glucopyranosyl-(1\rightarrow2)-\( 9251 \)-mannopyranosyl-(1\rightarrow2)-\( 9251 \)-mannopyranoside (9). (B) Induction of IFN-\( 9252 \) secretion in PBMC after stimulation with compounds 7 (○), 8 (■), and 9 (▲).
IFN-\( 9252 \) responses were measured as mRNA expression in PBMC with TaqMan.
Fold changes in the IFN-\( 9252 \) expression (mean and SEM) compared to that in the
unstimulated culture are shown on the y axis.

FIG 4 (A) Divalent structures of 1,4-bis(\( 9252 \)-mannopyranosyloxy)butane (10), 1,4-bis(\( 9252 \)-mannopyranosyl-(1\rightarrow2)-\( 9252 \)-mannopyranosyloxy)butane (11), 1,4-bis(cyclohexyl 2-O-\( 9252 \)-mannopyranosyl)butane (12), 1,4-bis(2-O-\( 9252 \)-mannopyranosyl)butane (13), 1,4-bis(2-O-\( 9252 \)-mannopyranosyl-(1\rightarrow2)-
\( 9252 \)-mannopyranosyl)butane (14), and 1,4-bis(methyl-\( 9251 \)-mannopyranosyl-
(2\rightarrow1)-2-O-\( 9252 \)-glucopyranosyl)butane (15). (B) Fold increases in PBMC
cytokine production after divalent oligosaccharide stimulations.
Production of IFN-\( 9252 \), IL-4, TNF, and IL-10 was measured (mean and SEM) with Luminex
at 72 h after stimulations with various concentrations of the divalent saccha-
ride compounds 10 (○), 11 (■), 12 (△), 13 (○), 14 (▲), and 15 (●).
tions, i.e., the mannosibioside with cyclohexyl or methyl aglycon (compounds 4 and 5, respectively) and the mannotrioside with methyl aglycon (compound 6), did not induce any measurable IFN-γ production in the PBMC (Fig. 2B). In order to investigate the significance of the stereochemistry at C-2 of the individual sugar units, the glucose- and N-acetyl glucosamine-containing analogues (compounds 7 to 9) with modifications to the nonreducing end of the oligosaccharide compound were likewise screened. Structurally related oligosaccharide fragments have been identified in the native C. albicans cell wall. These modified analogues did not, however, induce any cytokine production (Fig. 3B).

In contrast to simple monovalent oligosaccharides, the oligo- and multivalent carbohydrate assemblies may simultaneously interact with multiple receptors, potentially enhancing the binding affinities of such constructs and, hence, affecting the biological activities (22, 24, 25). As the most simple compounds for oligovalent mannoside structures, a series of divalent mono- and disaccharide-based constructs, prepared earlier by us using olefin cross-metathesis (9), were here screened for their potential immunostimulatory responses with a wider array of cytokines. However, none of the divalent compounds (compounds 10 to 15) investigated in the present work induced any measurable IL-4, IL-10, or IFN-γ responses. For one single compound, 1,4-bis(α-D-mannopyranosylxy)butane (compound 10), dose-dependent stimulation of TNF production was observed (Fig. 4B).

In summary, none of the synthetic oligomannosides investigated in the present work were shown to induce any significant cytokine production in the human white blood cell. One single divalent mannoside was shown to induce TNF production, whereas in contrast to earlier reports using native oligosaccharides from C. albicans, synthetic well-defined β-(1→2)-linked mannopentaose did not induce any TNF production in mouse macrophages. To conclude, the results obtained herein indicate that further studies are needed in order to verify that the biological responses that are assumed in earlier studies to stem from the β-(1→2)-linked oligomannosides are due solely to the presence of these molecules. It is possible that the heterogeneous native extracts also contain some other biologically active components partly contributing to the observed biological activities. Similarly, further synthetic efforts should be directed toward preparation of truly multivalent β-(1→2)-oligomannosides and their analogues for possible identification of synthetic immunostimulatory molecular candidates.

ACKNOWLEDGMENTS

This work was supported by grants from the Finnish Funding Agency for Technology and Innovation, Tekes (project 40134/06), The Finnish Society of Allergology and Immunology, Sigrid Juselius Foundation, Allergy Research Foundation of South-Western Finland, Allergy Research Foundation, The University Central Hospital of Turku, and the Academy of Finland (project numbers 121216, 121334, and 121335).

We thank Leena Kavén-Honka for her excellent technical assistance.

REFERENCES

1. Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17:593–623.
2. Akdis CA, Blaser K. 1999. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy, FASEB J. 13:603–609.
3. Bellinghausen I, et al. 1997. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27:1131–1139.
4. Bland E, Keshavarz T, Bucke C. 2004. The influence of small oligosaccharides on the immune system. Carbohydr. Res. 339:1673–1678.
5. Cambi A, et al. 2003. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur. J. Immunol. 33:532–538.
6. Cassone A, et al. 1988. Production and characterization of a monoclonal antibody to a cell-surface, glucomannoprotein constituent of Candida albicans and other pathogenic Candida species. J. Med. Microbiol. 27:233–238.
7. Crich D, Banerjee A, Yao Q. 2004. Direct chemical synthesis of the the β-(1→4)-mannan: the β-(1→2) and β-(1→4) series. J. Am. Chem. Soc. 126:14930–14934.
8. Cutler JE. 2001. N-glycosylation of yeast, with emphasis on Candida albicans. Med. Mycol. 39(Suppl 1):75–86.
9. Ekholm FS, Polakóvá M, Pawłowicz AJ, Leino R. 2009. Synthesis of divalent 2,2′-linked mannose derivatives by homodimerization. Synthesis 4:567–576.
10. Ekholm FS, Sinkkonen J, Leino R. 2010. Fully deprotected β-(1→2)-mannopentaose forms a contorted α-helix in solution: convergent synthesis and conformational characterization by NMR and DFT. New J. Chem. 34:667–675.
11. Fiani ML, Beitz J, Turvy D, Blum JS, Stahl PD. 1998. Regulation of mannose receptor synthesis and turnover in mouse J774 macrophages. J. Leukoc. Biol. 64:85–91.
12. Fradin C, et al. 1996. Beta-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage. J. Leukoc. Biol. 60:81–87.
13. Fradin C, Poulaud D, Jouault T. 2000. β-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lecithin-germ-3. Infect. Immun. 68:4391–4398.
14. Gerner RE, Rubanowice K, Sawyer RT, Hudson JA. 1994. Secretion of TNF-α by alveolar macrophages in response to Candida albicans mannan. J. Leukoc. Biol. 55:161–168.
15. Janusz MJ, Austen KE, Czop JK. 1989. Isolation of a yeast heptaglucoside that inhibits monocyte phagocytosis of zymosan particles. J. Immunol. 142:959–965.
16. Jouault T, Bernignaud A, Lepage G, Trinel P, Poulain D. 1994. The Candida albicans phospholipomannan induces in vitro production of tumour necrosis factor-α from human and murine macrophages. Immunology 83:268–273.
17. Jouault T, et al. 2006. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J. Immunol. 177:4679–4687.
18. Jouault T, Fradin C, Trinel PA, Poulaud D. 2000. Candida albicans-derived β-1,2-linked mannooligosaccharides induce desensitization of macrophages. Infect. Immun. 68:965–968.
19. Jouault T, et al. 1995. β-1,2-linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production. Infect. Immun. 63:2378–2381.
20. Jutel M, et al. 2003. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33:1205–1214.
21. Jutel M, et al. 1995. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154:4817–4819.
22. Kiesling I, Gestwicki J, Strong L. 2006. Synthetic multivalent ligands as probes of signal transduction. Angew. Chem. Int. Ed. Engl. 45:2348–2368.
23. Kohatsu L, Hsu DK, Jegalian AG, Liu FT, Baum LG. 2006. Galectin-3 induces death of Candida species expressing specific β-1,2-linked mannan. J. Immunol. 177:4718–4726.
24. Lee R, Lee Y. 2000. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycocoj. 17:543–551.
25. Männil M, Choi S, Whitesides G. 1998. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. Engl. 37:2754–2794.
26. Masuoka J. 2004. Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin. Microbiol. Rev. 17:281–310.
27. Nakajima T, Ballou CE. 1974. Characterization of the carbohydrate frag-
ments obtained from *Saccharomyces cerevisiae* mannan by alkaline degradation. J. Biol. Chem. 249:7679–7684.

28. Poláková M, Roslund MU, Ekholm FS, Saloranta T, Leino R. 2009. Synthesis of β-(1–2)-linked oligomannosides. Eur. J. Org. Chem. 6:870–888.

29. Poulain D, Jouault T. 2004. *Candida albicans* cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr. Opin. Microbiol. 7:342–349.

30. Rolland J, O’Hehir R. 1998. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr. Opin. Immunol. 10:640–645.

31. Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO. 2004. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin. Exp. Allergy 34:413–419.

32. Schulert GS, Allen LAH. 2006. Differential infection of mononuclear phagocytes by *Francisella tularensis*: role of the macrophage mannose receptor. J. Leukoc. Biol. 80:563–571.

33. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. 1993. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 178:2123–2130.

34. Shibata N, et al. 1985. Immunochemical study on the mannans of *Candida albicans* NIH A-207, NIH B-792, and J-1012 strains prepared by fractional precipitation with cetyltrimethylammonium bromide. Arch. Biochem. Biophys. 243:338–348.

35. Trinel PA, et al. 1993. Isolation and preliminary characterization of the 14- to 18-kilodalton *Candida albicans* antigen as a phospholipomannan containing β-1,2-linked oligomannosides. Infect. Immun. 61:4398–4405.

36. Trinel PA, Faille C, Jacquinot PM, Cailliez JC, Poulain D. 1992. Mapping of *Candida albicans* oligomannosidic epitopes by using monoclonal antibodies. Infect. Immun. 60:3845–3851.

37. Vecchiarelli A, Puliti M, Torosantucci A, Cassone A, Bistoni F. 1991. In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of *Candida albicans* cell wall. Cell. Immunol. 134:65–76.